Advanced Search

 

Study ID Status Title Patient Level Data
207451 Not yet recruiting A Proof of Concept (POC) Clinical Study to Investigate the Effects of a Developmental Cosmetic Moisturising Cream on the Barrier Function of Human Skin on the Face and Forearm
207521 Completed PGx7673: Confirmatory Genetics Reporting and Analysis Plan: Efficacy pharmacogenetic analysis of SLE patients treated with Benlysta in study BEL113750 (eTrack Study ID 207521)
207524 Active not recruiting Quantitative Testing of Prescriber Knowledge about TANZEUMTM (albiglutide) Safety and Use Information
207545 Not yet recruiting A Bite Force Study Assessing Two Currently Marketed Denture Adhesive Products Compared to No-Adhesive Control.
207620 Not yet recruiting A cross-sectional study to characterize the prevalence of COPD and eosinophilia among primary care patients in Brazil
207625 Active not recruiting Meta analysis to estimate the bacteriological treatment effect of nitrofurantoin for determination of the non-inferiority margin in uUTI
207644 Active not recruiting Meta analysis of HPV-associated cases in efficacy studies according to baseline cytology and DNA status
208108/091 Completed A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects Study Listed on ClinicalStudyDataRequest.com
208109/220 Completed A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age Study Listed on ClinicalStudyDataRequest.com
208109/231 Completed Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Study Listed on ClinicalStudyDataRequest.com
208109/232 Completed Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age Study Listed on ClinicalStudyDataRequest.com
208127/132 (EXT Y2) Completed Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose Study Listed on ClinicalStudyDataRequest.com
208129/002 Completed Study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine versus Engerix™-B, in haemodialysis patients
208129/004 Completed Study to evaluate the immunogenicity and reactogenicity of GSK Biologicals' MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following 2 different schedules
208129/005 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers
208129/006 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals' (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine in healthy adult volunteers
208129/009 Completed Study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccines with and without adjuvant in healthy older adult volunteers
208129/016 Completed Study to compare the safety, immunogenicity and reactogenicity of different formulations of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine to that of Engerix™-B
208129/019 Completed Study to assess the safety, immunogenicity and reactogenicity of GSK Biologicals' (previously SmithKline Beecham Biologicals') adjuvanted recombinant hepatitis B vaccine, recombinant hepatitis B vaccine new formulation and Engerix™-B
208129/021 Completed Study to compare the immunogenicity and reactogenicity of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine with that of Engerix™-B in an adult non-responder population
208129/022 Completed Study comparing immunogenicity, reactogenicity and safety of GSK Biologicals' HBV-MPL vaccine with that of Engerix™-B when both are injected according to 3 dose schedule (0, 1, 6 months) in an adult population aged between 50 and 70 years
208129/025 Completed Study comparing the immunogenicity and reactogenicity of different formulations of GSK Biologicals' HBV-MPL vaccine injected as a 0, 6 months schedule with that of Engerix™-B injected as a 0, 1, 6 months schedule in healthy adults aged 18-40 years
208129/026 Completed Study comparing the immunogenicity and reactogenicity of different formulations of GSK Biologicals' HBV-MPL vaccine injected as a 0, 6 months schedule with that of Engerix™-B injected as a 0, 1, 6 months schedule in healthy adults aged 19-40 years
208129/027 Completed Study comparing the immunogenicity and reactogenicity of GSK Biologicals' HBV-MPL vaccine injected according to a 0, 6 months schedule with that of Engerix™-B injected as a 0, 1, 6 months schedule in a healthy adult population (15-40 years)
208129/028 Completed Study to assess the feasibility of GSK Biologicals' candidate HBV / MPL vaccines following different schedules and formulations and to compare their safety and immunogenicity to that of Engerix™-B in healthy adolescents aged 11 to 15 years

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.